<div id="readability-page-1"><div><h2>Recent performance context for BioMarin Pharmaceutical (BMRN)</h2> <p>BioMarin Pharmaceutical (BMRN) has been under pressure recently, with the stock down about 4% over the past day, 6% over the past week, and 9% over the past month.</p> <p>Over the past 3 months the share price has fallen roughly 17%, and the 1 year total return is down about 16%. This sets a cautious backdrop for assessing the company’s current valuation and fundamentals.</p> <p>See our latest analysis for BioMarin Pharmaceutical.</p> <p>With the latest share price at US$49.67, BioMarin’s weak 1-day and 30-day share price returns continue a broader downtrend, and the multi year total shareholder return data indicates momentum has been fading rather than building.</p> <p>If you are reassessing your exposure to biotech, this can be a good moment to broaden your watchlist and scan for other opportunities using our 31 healthcare AI stocks</p> <p>With BioMarin’s share price under pressure, but the stock trading at a large discount to one widely followed analyst price target and an internal intrinsic value estimate, is this weakness a potential entry point or is the market already factoring in future growth?</p> <h2>Most Popular Narrative: 45% Undervalued</h2> <p>Compared with the last close of US$49.67, the most followed fair value estimate of US$89.96 points to a wide gap that hinges on future earnings power and margin recovery.</p> <blockquote> <p><em>Analysts expect earnings to reach $1.3 billion (and earnings per share of $6.6) by about May 2029, up from $268.7 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $2.1 billion in earnings, and the most bearish expecting $746.2 million.</em></p> </blockquote> <p><em>Read the complete narrative.</em></p> <p>Want to see what bridges that valuation gap? The narrative leans heavily on compounding revenue, rising margins and a future earnings multiple that is far from conservative.</p> <p><strong>Result: Fair Value of $89.96 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, there are clear watchpoints here, including Voxzogo competition and pricing pressure, as well as higher R&amp;D and SG&amp;A spending, all capable of challenging that upbeat earnings narrative.</p> <p>Find out about the key risks to this BioMarin Pharmaceutical narrative.</p> <h2>Another View: Earnings Multiple Sends a Different Signal</h2> <p>The fair value narrative suggests BioMarin looks cheap, yet the current P/E of 35.7x is very rich compared with the US Biotechs industry at 17.2x, peers at 18.7x and a fair ratio of 23x. That gap points to meaningful valuation risk if sentiment or growth expectations reset.</p> <p>To see how that richer P/E stacks up against the underlying numbers and where the market could shift if it gravitates toward the fair ratio, See what the numbers say about this price — find out in our valuation breakdown.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d82970fc-b076-4cd1-b6f6-ff36f82ecfcf/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTE5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d82970fc-b076-4cd1-b6f6-ff36f82ecfcf/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTE5"/><figcaption>NasdaqGS:BMRN P/E Ratio as at May 2026</figcaption></figure><h2>Next Steps</h2> <p>If this combination of pressure and potential feels conflicting to you, that is exactly why it can be useful to move quickly, review the underlying data, and weigh both sides of the story for yourself using the 2 key rewards and 3 important warning signs</p> <h2>Looking for more investment ideas?</h2> <p>Do not stop your research with one stock. Use focused stock lists to surface other opportunities that might suit your risk tolerance and income goals.</p> <ul> <li>Target steady income potential by reviewing 12 dividend fortresses with payout profiles that may appeal if you want yield to play a bigger role in your portfolio.</li> <li>Hunt for potential value opportunities by checking 51 high quality undervalued stocks that combine solid fundamentals with prices that may sit below their assessed worth.</li> <li>Dial back risk by scanning 65 resilient stocks with low risk scores that pair resilient balance sheets with more measured volatility so sharp drawdowns are less likely to catch you off guard.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if BioMarin Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

BMRN

SBIO

<p>BioMarin Pharmaceutical (BMRN) has seen a decline in its stock price, down 4% in a day and 17% over three months, raising concerns about its valuation. Currently priced at $49.67, analysts estimate a fair value of $89.96, indicating potential undervaluation. However, there is significant disagreement among analysts regarding future earnings projections. The company's high P/E ratio of 35.7x compared to industry averages suggests valuation risks. Investors are advised to consider both opportunities and risks before making decisions.</p>

Simplywall

BioMarin Pharma

SPDR S&P Biotech

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

VG Health

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares US Pharma

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

VanEck Biotech ETF

iShares Biotechnology ETF

Assessing BioMarin Pharmaceutical (BMRN) Valuation After Prolonged Share Price Weakness